Filing Details
- Accession Number:
- 0001193125-21-279369
- Form Type:
- 13G Filing
- Publication Date:
- 2021-09-21 20:00:00
- Filed By:
- Fairmount Funds Management Llc
- Company:
- Astria Therapeutics Inc. (NASDAQ:ATXS)
- Filing Date:
- 2021-09-22
- SEC Url:
- 13G Filing
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
---|---|---|---|---|---|---|
Fairmount Funds Management | 0 | 974,605 | 0 | 974,605 | 974,605 | 7.6% |
Fairmount SPV I | 0 | 292,579 | 0 | 292,579 | 292,579 | 2.3% |
Fairmount SPV II | 0 | 143,027 | 0 | 143,027 | 143,027 | 1.1% |
Fairmount Healthcare Fund GP | 0 | 45,166 | 0 | 45,166 | 45,166 | 0.4% |
Fairmount Healthcare Fund II GP | 0 | 493,833 | 0 | 493,833 | 493,833 | 3.9% |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No.1)*
Astria Therapeutics, Inc.
(Name of Issuer)
Common Stock, Par Value $0.001
(Title of Class of Securities)
04635X102
(CUSIP Number)
James J. Moloney
Gibson, Dunn & Crutcher LLP
3161 Michelson Drive
Irvine, CA 92612
(949) 451-3800
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
September 20, 2021
(Date of Event Which Requires Filing of This Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)
☒ Rule 13d-1(c)
☐ Rule 13d-1(d)
* | The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. |
The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 04635X102 |
1. | Names of Reporting Persons I.R.S. Identification No. of Above Persons (Entities Only)
Fairmount Funds Management LLC | |||||
2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐
| |||||
3. | SEC Use Only
| |||||
4. | Citizenship or Place of Organization
Delaware | |||||
Number of Shares Beneficially Owned by Each Reporting Person With | 5. | Sole Voting Power
0 | ||||
6. | Shared Voting Power
974,605 | |||||
7. | Sole Dispositive Power
0 | |||||
8. | Shared Dispositive Power
974,605 | |||||
9. | Aggregate Amount Beneficially Owned by Each Reporting Person
974,605 | |||||
10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
| |||||
11. | Percent of Class Represented by Amount in Row (9)
7.6%(1) | |||||
12. | Type of Reporting Person (See Instructions)
IA |
(1) | Calculated based on 12,824,787 shares of the Issuers Common Stock outstanding, as disclosed in the Current Report on Form 8-K filed by the Issuer with the Securities and Exchange Commission on September 8, 2021. |
CUSIP No. 04635X102
1. | Names of Reporting Persons I.R.S. Identification No. of Above Persons (Entities Only)
Fairmount SPV I, LLC | |||||
2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐
| |||||
3. | SEC Use Only
| |||||
4. | Citizenship or Place of Organization
Delaware | |||||
Number of Shares Beneficially Owned by Each Reporting Person With | 5. | Sole Voting Power
0 | ||||
6. | Shared Voting Power
292,579 | |||||
7. | Sole Dispositive Power
0 | |||||
8. | Shared Dispositive Power
292,579 | |||||
9. | Aggregate Amount Beneficially Owned by Each Reporting Person
292,579 | |||||
10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
| |||||
11. | Percent of Class Represented by Amount in Row (9)
2.3%(1) | |||||
12. | Type of Reporting Person (See Instructions)
OO |
(1) | Calculated based on 12,824,787 shares of the Issuers Common Stock outstanding, as disclosed in the Current Report on Form 8-K filed by the Issuer with the Securities and Exchange Commission on September 8, 2021. |
CUSIP No. 04635X102
1. | Names of Reporting Persons I.R.S. Identification No. of Above Persons (Entities Only)
Fairmount SPV II, LLC | |||||
2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐
| |||||
3. | SEC Use Only
| |||||
4. | Citizenship or Place of Organization
Delaware | |||||
Number of Shares Beneficially Owned by Each Reporting Person With | 5. | Sole Voting Power
0 | ||||
6. | Shared Voting Power
143,027 | |||||
7. | Sole Dispositive Power
0 | |||||
8. | Shared Dispositive Power
143,027 | |||||
9. | Aggregate Amount Beneficially Owned by Each Reporting Person
143,027 | |||||
10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
| |||||
11. | Percent of Class Represented by Amount in Row (9)
1.1%(1) | |||||
12. | Type of Reporting Person (See Instructions)
OO |
(1) | Calculated based on 12,824,787 shares of the Issuers Common Stock outstanding, as disclosed in the Current Report on Form 8-K filed by the Issuer with the Securities and Exchange Commission on September 8, 2021. |
CUSIP No. 04635X102
1. | Names of Reporting Persons I.R.S. Identification No. of Above Persons (Entities Only)
Fairmount Healthcare Fund GP LLC | |||||
2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐
| |||||
3. | SEC Use Only
| |||||
4. | Citizenship or Place of Organization
Delaware | |||||
Number of Shares Beneficially Owned by Each Reporting Person With | 5. | Sole Voting Power
0 | ||||
6. | Shared Voting Power
45,166 | |||||
7. | Sole Dispositive Power
0 | |||||
8. | Shared Dispositive Power
45,166 | |||||
9. | Aggregate Amount Beneficially Owned by Each Reporting Person
45,166 | |||||
10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
| |||||
11. | Percent of Class Represented by Amount in Row (9)
0.4%(1) | |||||
12. | Type of Reporting Person (See Instructions)
OO |
(1) | Calculated based on 12,824,787 shares of the Issuers Common Stock outstanding, as disclosed in the Current Report on Form 8-K filed by the Issuer with the Securities and Exchange Commission on September 8, 2021. |
CUSIP No. 04635X102
1. | Names of Reporting Persons I.R.S. Identification No. of Above Persons (Entities Only)
Fairmount Healthcare Fund II GP LLC | |||||
2. | Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐
| |||||
3. | SEC Use Only
| |||||
4. | Citizenship or Place of Organization
Delaware | |||||
Number of Shares Beneficially Owned by Each Reporting Person With | 5. | Sole Voting Power
0 | ||||
6. | Shared Voting Power
493,833 | |||||
7. | Sole Dispositive Power
0 | |||||
8. | Shared Dispositive Power
493,833 | |||||
9. | Aggregate Amount Beneficially Owned by Each Reporting Person
493,833 | |||||
10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
| |||||
11. | Percent of Class Represented by Amount in Row (9)
3.9%(1) | |||||
12. | Type of Reporting Person (See Instructions)
OO |
(1) | Calculated based on 12,824,787 shares of the Issuers Common Stock outstanding, as disclosed in the Current Report on Form 8-K filed by the Issuer with the Securities and Exchange Commission on September 8, 2021. |
Item 1. |
(a) Name of Issuer |
Astria Therapeutics, Inc.* |
* Effective as of September 8, 2021, Catabasis Pharmaceuticals, Inc. (the Company) amended its certificate of incorporation to effect a change of the Companys name from Catabasis Pharmaceuticals, Inc. to Astria Therapeutics, Inc. |
(b) Address of Issuers Principal Executive Offices |
100 High Street, 28th Floor, Boston, MA 02110 |
Item 2. |
This Amendment No. 1 to Schedule 13G amends and restates the Statement on Schedule 13G filed on June 17, 2021. |
(a) Name of Person(s) Filing: |
(A) Fairmount Funds Management LLC |
(B) Fairmount SPV I, LLC |
(C) Fairmount SPV II, LLC |
(D) Fairmount Healthcare Fund GP LLC |
(E) Fairmount Healthcare Fund II GP LLC |
(b) Address of Principal Business Office or, if none, Residence: |
(A) 2001 Market St., Suite 2500, Philadelphia, PA 19103 |
(B) 2001 Market St., Suite 2500, Philadelphia, PA 19103 |
(C) 2001 Market St., Suite 2500, Philadelphia, PA 19103 |
(D) 2001 Market St., Suite 2500, Philadelphia, PA 19103 |
(E) 2001 Market St., Suite 2500, Philadelphia, PA 19103 |
(c) Citizenship: |
(A) Delaware |
(B) Delaware |
(C) Delaware |
(D) Delaware |
(E) Delaware |
(d) Title of Class of Securities: |
Common Stock, Par Value $0.001 |
(e) CUSIP Number: |
04635X102 |
Item 3. | If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: |
Not applicable.
(a) | ☐ | Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o); | ||
(b) | ☐ | Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); | ||
(c) | ☐ | Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); | ||
(d) | ☐ | Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); | ||
(e) | ☐ | An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); | ||
(f) | ☐ | An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); | ||
(g) | ☐ | A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G); | ||
(h) | ☐ | A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); | ||
(i) | ☐ | A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); | ||
(j) | ☐ | A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J); | ||
(k) | ☐ | Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: . |
Item 4. | Ownership |
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
(a), (b), and (c)
Reporting Persons* | Number of Shares With Sole Voting and Dispositive Power | Number of Shares With Shared Voting and Dispositive Power | Aggregate Number of Shares Beneficially Owned | Percentage of Class Beneficially Owned** | ||||||||||||
Fairmount Funds Management LLC | 0 | 974,605 | 974,605 | 7.6 | % | |||||||||||
Fairmount SPV I, LLC | 0 | 292,579 | 292,579 | 2.3 | % | |||||||||||
Fairmount SPV II, LLC | 0 | 143,027 | 143,027 | 1.1 | % | |||||||||||
Fairmount Healthcare Fund GP LLC | 0 | 45,166 | 45,166 | 0.4 | % | |||||||||||
Fairmount Healthcare Fund II GP LLC | 0 | 493,833 | 493,833 | 3.9 | % |
* | The above figures reflect the most recent beneficial ownership for the Reporting Persons above as of September 8, 2021. |
** | The percentages reported above are calculated based on 12,824,787 shares of the Issuers Common Stock outstanding as reported on September 8, 2021. Percentages shown above subject to rounding adjustments. |
Item 5. | Ownership of Five Percent or Less of a Class |
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.
Item 6. | Ownership of More than Five Percent on Behalf of Another Person |
Not applicable.
Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person |
Not applicable.
Item 8. | Identification and Classification of Members of the Group |
Not applicable.
Item 9. | Notice of Dissolution of Group |
Not applicable.
Item 10. | Certification |
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Signature
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: September 22, 2021
FAIRMOUNT FUNDS MANAGEMENT LLC | ||||
By: | /s/ Peter Harwin | /s/ Tomas Kiselak | ||
Name: | Peter Harwin | Tomas Kiselak | ||
Title: | Managing Member | Managing Member | ||
FAIRMOUNT SPV I, LLC | ||||
By: | /s/ Peter Harwin | /s/ Tomas Kiselak | ||
Name: | Peter Harwin | Tomas Kiselak | ||
Title: | Managing Member | Managing Member | ||
FAIRMOUNT SPV II, LLC | ||||
By: | /s/ Peter Harwin | /s/ Tomas Kiselak | ||
Name: | Peter Harwin | Tomas Kiselak | ||
Title: | Managing Member | Managing Member | ||
FAIRMOUNT HEALTHCARE FUND GP LLC | ||||
By: | /s/ Peter Harwin | /s/ Tomas Kiselak | ||
Name: | Peter Harwin | Tomas Kiselak | ||
Title: | Managing Member | Managing Member | ||
FAIRMOUNT HEALTHCARE FUND II GP LLC | ||||
By: | /s/ Peter Harwin | /s/ Tomas Kiselak | ||
Name: | Peter Harwin | Tomas Kiselak | ||
Title: | Managing Member | Managing Member |